Singapore Clinical Trial: DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA AT HIGH RISK OF ACUTE PANCREATITIS (SHASTA-5 STUDY)

Posted On: 2026-03-28

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA AT HIGH RISK OF ACUTE PANCREATITIS (SHASTA-5 STUDY)'. The following are the other relevant details related to the trial:

Therapeutic Area: Endocrinology & Metabolism

Trial Centre(s): Khoo Teck Puat Hospital

Trial Status: NA

Principal Investigator(s): Dr Sanjaya Dissanayake

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Singapore Clinical Trial: DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA AT HIGH RISK OF ACUTE PANCREATITIS (SHASTA-5 STUDY)